Capital Fund Management (CFM)
IOVA icon

Capital Fund Management (CFM)’s Iovance Biotherapeutics IOVA Stock Holding History

Capital Fund Management (CFM)’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,900
Closed -$243K – 2136
2024
Q3 		$243K Buy
+25,900
New +$245K ﹤0.01% 1926

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Capital Fund Management (CFM)'s IOVA Position: Q1 2026 in Review

Capital Fund Management (CFM) sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 181,074 shares — an estimated $494K sold.

Capital Fund Management (CFM) first reported a position in IOVA in Q3 2022 and held it in 12 quarters. The position peaked at $3.89M in Q3 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Capital Fund Management (CFM) reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 181,074 Iovance Biotherapeutics shares in Q1 2026, an estimated $494K.
  • Capital Fund Management (CFM) first reported a position in Iovance Biotherapeutics in Q3 2022 and held it in 12 quarters.
  • Capital Fund Management (CFM)'s Iovance Biotherapeutics position peaked at $3.89M in Q3 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.